Treating metastatic prostate cancer with microRNA-145

Author(s)

Iscaife, Alexandre ^[1] ; Reis, Sabrina Thalita ^[1] ; Morais, Denis Reis ^[1] ; Viana, Nayara Izabel ^[1] ; da Silva, Iran Amorim ^[1] ; Pimenta, Ruan ^[1] ; Bordini, Andre ^[1] ; Dip, Nelson ^[1] ; Srougi, Miguel ^[1] ; Moreira Leite, Katia Ramos ^[1]

Affiliation

^[1] Univ Sao Paulo, Fac Med FMUSP, Lab Invest Med, Disciplina Urol LIM 55, Av Dr Arnaldo 455, Sala 2145, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: Apoptosis; v. 23, n. 7-8, p. 388-395, AUG 2018.
• Web of Science Citations: 4

Abstract

Prostate cancer (PCa) is an incurable disease at the metastatic stage. Although there are different options for treatment, the results are limited. MicroRNAs (miRNAs) are a group of small, noncoding, regulatory RNAs with important roles in regulating gene expression. miR-145 is reported to be a key tumor suppressor miRNA (tsmiR) that controls important oncogenes, such as MYC and RAS. In this study, in vitro studies were performed to show the control of MYC and RAS by miR-145. Flow cytometry was used to analyze cell proliferation and apoptosis. The efficacy of miR-145 in treating metastatic PCa was tested in nude mice using a model of bone metastasis promoted by intraventricular injection of PC-3MLuc-C6 cells. Tumor growth was evaluated by an in vivo bioluminescence system. After the full establishment of metastases on day 21, six animals were treated with three intravenous doses of miR-145 (on days 21, 24 and 27), and six were injected with scramble miRNA as controls. Compared to the controls, tumor growth was significantly reduced in animals receiving miR-145, most importantly on day 7 after the third and last dose of miRNA. After discontinuing the treatment, tumor growth resumed, becoming similar to the group of non-treated animals. A decrease in MYC and RAS expression was observed in all cell lines after treatment with miR-145, although statistical significance was achieved only in experiments with LNCaP and PC3 cell lines, with a decrease in 56% (p = 0.012) and 31% (p = 0.013) of RAS expression, respectively. Our results suggest that miR-145 is a potential molecule to be tested for treatment of metastatic, castration-resistant PCa. (AU)

• FAPESP's process: 13/07350-7 - The microRNA use for the treatment of prostate cancer: studies in vitro and in vivo
• Grantee: Alexandre Iscaife
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
• FAPESP's process: 12/21966-8 - The use of microRNA for the treatment of prostate cancer: studies in vitro and in vivo
• Grantee: Kátia Ramos Moreira Leite
• Support Opportunities: Regular Research Grants